Healthcare investment professional Dr. Mitchell Blutt founded Consonance Capital in 2005 and has served as its CEO since then. An active member of the healthcare community, Dr. Mitchell Blutt has been involved with various healthcare foundations such as the Michael J. Fox Foundation.
Each year, the Michael J. Fox Foundation works toward the goal of curing Parkinson’s disease by funding crucial research and supporting the creation of innovative therapies. Focused primarily on improving the lives of Parkinson’s patients, the organization also provides all the information individuals need to understand their various treatment options.
Medication is one of the first therapies physicians recommend to those living with Parkinson’s disease. Though these prescriptions help lessen symptoms of the condition, they cannot slow or reverse the disease itself. In general, Parkinson’s disease medications target two sets of symptoms: motor and non-motor. The former helps alleviate the muscle tremors and sluggishness that the condition manifests in patients. The latter complements physical treatment by providing relief from symptoms such as sleep deprivation and depression.
When medications are not enough to help patients manage their symptoms, physicians often will turn to deep brain stimulation as an alternative method of treatment. Those who receive this therapy must undergo a surgical procedure in which they receive electrode implants in their brain. By connecting to an external device, these electrodes administer small pulses to the parts of the brain that generate motor symptoms.
New York Academy of Medicine
A physician and business leader focused on healthcare investment, Dr. Mitchell Blutt serves as CEO of Consonance Capital, a New York City-based firm he founded in 2005. Additionally, he has taught as a professor at Weill Cornell Medical College for nearly three decades. Over the course of his career, Dr. Mitchell Blutt has maintained memberships in organizations such as The New York Academy of Medicine.
In addition to pursuing various research, policy, and program initiatives, The New York Academy of Medicine oversees a library that features a world-renowned collection of texts and other materials on medicine and public health. Recently, the Academy announced that Kriota Willberg will serve as the library’s first-ever Artist in Residence.
Willberg, a visual artist who teaches musculoskeletal anatomy to other artists as well as dancers and massage therapists, has collaborated with the academy in the past on anatomy drawing workshops and demonstrations. As the library’s Artist in Residence, she will explore the intersections between art and the body sciences and will hold workshops and classes for peers and students.
More information about Kriota Willberg and her appointment as the Artist in Residence at the New York Academy of Medicine’s library can be found at www.nyam.org/news.
Dr. Mitchell Blutt graduated with an MD from the University of Pennsylvania School of Medicine in 1982. Now an experienced healthcare investor, Dr. Mitchell Blutt also holds an MBA from the University of Pennsylvania Wharton School of Business and membership with the New York Academy of Medicine.
The New York Academy of Medicine was created in 1847 to help promote the advancement of health and well-being for people living in urban areas. The Academy produces several regular publications regarding its studies, including City Voices: New Yorkers on Health. The publication seeks to create a voice for the older and lower income residents of the city who tend to go unheard.
City Voices: New Yorkers on Health focuses on the personal experiences of low-income residents in the five boroughs to help influence decision making regarding health issues for the communities. The publication’s data brief Aging: Health Challenges and the Role of Social Connections covered an age range up to 102 as well as all races and ethnicities. The study found a relatively high degree of chronic diseases and many challenges in obtaining available geriatric services.
Dr. Mitchell Blutt works as a clinical assistant professor of medicine at Weill Cornell Medical College. A graduate of the University of Pennsylvania’s medical school, Dr. Mitchell Blutt served on the board of Penn Medicine, the university’s medical center, which trains doctors and advances medical research in addition to providing patient care.
At Penn Medicine, conducting research is an integral part of developing effective treatments. The process of turning research done in a laboratory into new drugs or treatment protocols that can be used to improve patients’ health is called translational research or “bench to bedside” medicine. The Institute for Translational Medicine and Therapeutics at Penn Medicine supports this work through providing the research facilities and faculty to turn medical research into treatments and procedures that can be applied in clinical settings to help patients heal.
In November 2016, research by University of Pennsylvania faculty member Mitchell Lazar, MD, PhD, illustrated a complementary relationship between two molecules in the liver – one that stores fat and one that helps burn fat. If the molecules are both removed in mice, toxic fats build up and can cause nonalcoholic steatohepatitis, also called non-alcoholic fatty liver disease. An important discovery, the findings may be used by those studying obesity to eventually develop treatments or drugs to reverse or prevent liver damage caused by overeating.